Cryopreserved-thawed embryo transfer in natural or down-regulated hormonally controlled cycles: a retrospective study

Fertil Steril. 2006 Mar;85(3):603-9. doi: 10.1016/j.fertnstert.2005.09.015.

Abstract

Objective: To assess the implantation, pregnancy, and live birth rates after the transfer of frozen-thawed embryos (FET) in a natural or hormonal control cycle.

Design: Retrospective study.

Setting: National Health Service tertiary referral center for reproductive medicine in Manchester, United Kingdom.

Patient(s): Two comparable groups of women with regular menstrual cycles: Group A (n = 212) had FET in a natural cycle after spontaneous ovulation; group B (n = 205) had FET in a pituitary-desensitized hormonally controlled cycle.

Intervention(s): In group B, GnRH agonist was commenced in the midluteal phase of the previous cycle and discontinued 3 days before embryo transfer. Oral estradiol valerate and vaginal progesterone pessary were used to prepare the endometrium. Embryo transfer was carried out 3 days after detection of the endogenous LH surge in group A and on day 3 of progesterone administration in group B.

Main outcome measure(s): Implantation, pregnancy, and live birth rates per cycle and per embryo transfer (ET).

Result(s): In the 212 women who had natural-cycle FET, 172 ETs were performed and 247 embryos replaced. The implantation rate was 14.1% (35/247). Twenty clinical pregnancies (20/172, 11.6%) were achieved. In the 205 women who had down-regulated hormone replacement-cycle FET, 173 embryo transfers were performed and 243 embryos replaced. The implantation rate was 13.5% (33/243). Eighteen clinical pregnancies (18/173, 10.2%) were achieved. There were no significant differences between the two groups with regard to the implantation, clinical pregnancy, or live birth rates per cycle or per ET.

Conclusion(s): These findings suggest that both FET protocols are equally effective in terms of implantation rate and pregnancy outcome in women with regular menstrual cycles.

MeSH terms

  • Administration, Intravaginal
  • Administration, Oral
  • Birth Rate
  • Cryopreservation*
  • Embryo Implantation
  • Embryo Transfer*
  • Endometrium / drug effects
  • Estradiol / administration & dosage
  • Estradiol / analogs & derivatives*
  • Estradiol / therapeutic use
  • Female
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Live Birth
  • Luteal Phase*
  • Luteinizing Hormone / blood
  • Menstrual Cycle
  • Pessaries
  • Pregnancy
  • Pregnancy Rate
  • Progesterone / administration & dosage*
  • Progesterone / therapeutic use
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Gonadotropin-Releasing Hormone
  • Progesterone
  • Estradiol
  • Luteinizing Hormone